雙成藥業(002693.SZ):維樂藥業起訴福建朗創藥業合同糾紛一案 已獲法院立案審理
格隆匯 10 月 20日丨雙成藥業(002693.SZ)公佈,公司全資子公司海南維樂藥業有限公司(“維樂藥業”、“原告”)於近日收到福建省福州市倉山區人民法院出具的《受理案件通知書》【(2020)閩0104民初5566號】,維樂藥業起訴福建朗創藥業有限公司(“被告”)合同糾紛一案,福建省福州市倉山區人民法院經審查後認為符合法定受理條件,決定立案審理。
訴訟請求:1、判令被告立即向原告償付補償款本金人民幣872.15萬元;2、判令被告立即向原告償付延遲支付補償款利息合計人民幣260.03萬元(暫計至2020年6月30日),利息直至清償完畢為止;以上1、2項共計金額為人民幣1132.18萬元。3、判令被告承擔本案訴訟費用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.